ASAn‐Sofie Schoonjans

An‐Sofie Schoonjans

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


An‐Sofie Schoonjans has a total of 218 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Three-Dimensional Gait Analysis in STXBP1-Related Disorder

    by Merel Swinnen, Lis Gys, Kim Marie Thalwitzer, Axel Deporte, Charlotte Van Gorp, Eileen Vermeer, Firooz Salami, Sarah Weckhuysen, Sebastian I. Wolf, Steffen Syrbe, et al.

    Background and ObjectivesSTXBP1-related disorder (STXBP1-RD), caused by pathogenic variants in the STXBP1 gene, is a rare neurodevelopmental condition, characterized by early-onset seizures, develo...

  • Open Access

    Long-read genome sequencing resolves complex structural variants in exome-negative developmental and epileptic encephalopathy

    by Joohyun Park, Zakaria Eddafir, Josua Kegele, Davide Mei, Noor Smal, Christina Vossler-Wolf, Kornelia Ellwanger, Charissa Millevert, Merel Swinnen, Robert Lauerer-Braun, et al.

    Background and Objectives: Developmental and Epileptic Encephalopathies (DEEs) encompass a clinically and molecularly heterogeneous group of mainly genetic disorders. Despite standard genetic testing, approximately two-thirds of patients remain undiagnosed. Pathogenic noncoding and structural variants (SVs), particularly complex rearrangements that are difficult to detect or resolve using short-read sequencing, may contribute to this diagnostic gap. To evaluate the diagnostic contribution of long-read genome sequencing (lrGS), we recruited a cohort of 124 families with sporadic DEE who remained unsolved by prior ES. Methods: Trio lrGS (Oxford Nanopore or PacBio HiFi) was performed, complemented zby short-read genome sequencing (srGS) and mRNA sequencing (blood or fibroblast) of index cases, where available. Comprehensive variant analysis included small nucleotide variants (SNVs), indels, SVs, and short tandem repeats. To identify the diagnostic yield of each method, we compared lrGS, srGS and ES re-analysis, and evaluated the additional value of RNA sequencing. Results: We established a diagnosis in 21 of 124 families (16.9%). Fourteen variants were retrospectively detectable in prior ES., Two cases with non-coding variants in SCN1A and RNU2-2 were detectable by both srGS and lrGS. Five SVs also required genome sequencing (5.6% of the total cohort), three of which could be detected, but not confidently resolved by srGS due to breakpoint complexity, repeat-mediated rearrangements, and large copy-neutral events: LrGS enabled accurate characterization of Alu-mediated CDKL5 and STXBP1 deletions and a MEF2C deletion with large inversion. A copy-neutral SCN1A inversion was well characterizable by both srGS and lrGS. One balanced translocation t(X;17) disrupting CDKL5 was resolved by lrGS (srGS unavailable). RNA sequencing confirmed pathogenicity of two SVs including t(X;17), the MEF2C deletion with inversion, and two CNVs. In addition, ZNF569 and ZNF570 emerged as candidate epilepsy genes from our cohort. Discussion: In ES-negative DEE, the incremental diagnostic yield of genome sequencing was modest, while lrGS provided particular value for the structural resolution of complex rearrangements, especially those involving repetitive sequences. The finding that two-thirds of diagnoses were retrospectively detectable in prior ES highlights the substantial value of systematic reanalysis. Further gains from genome sequencing may increasingly depend on improved interpretation of non-coding variation and integration of long-read-specific information. Our findings indicate that complex SVs represent the class for which lrGS currently yields the most distinctive diagnostic information.

  • Open Access

    Efficacy and safety of fenfluramine in Dravet syndrome: The impact of patient clinical characteristics

    by Rima Nabbout, Joseph Sullivan, Stéphane Auvin, J. Helen Cross, Orrin Devinsky, Antonio Gil‐Nagel, Renzo Guerrini, Kelly G. Knupp, M. Scott Perry, Rocío Sánchez‐Carpintero, et al.

    Objective: To assess the efficacy and safety of fenfluramine in patients with Dravet syndrome (DS) stratified by age, number of previously attempted antiseizure medications (ASMs), and SCN1A pathogenic variant status. Methods: In this post hoc analysis, data from three randomized controlled trials (RCTs) in patients with DS (2–18 years) were pooled and stratified by age (SCN1A pathogenic variant status ( SCN1A +; SCN1A −). Stratified groups were assessed and compared with the pooled placebo group (change in monthly convulsive seizure frequency [MCSF], longest convulsive seizure‐free interval, and Clinical Global Impression–Improvement [CGI–I] scale scores rated by parents/caregivers and investigators), and safety (treatment‐emergent adverse events [TEAEs]: frequency, days to onset, and proportion resolved). Results: Among 348 patients included in the RCTs, 216 were randomized to fenfluramine (0.7 mg/kg/day, n = 88; 0.4 mg/kg/day [with stiripentol], n = 43; 0.2 mg/kg/day, n = 85) and 132 to placebo. Compared with placebo, fenfluramine treatment (all doses combined) resulted in greater MCSF reductions, greater increases in longest convulsive seizure‐free intervals, and a higher proportion of parents/caregivers and investigators reporting clinically meaningful improvement (“Much Improved”, “Very Much Improved”) on CGI–I scores across all stratified groups. CGI–I scores were consistent across fenfluramine doses in most stratified groups, but patients with the fewest number of previous ASMs had the greatest frequency of clinically meaningful improvement on investigator‐rated CGI–I scores. Safety outcomes were similar across all strata. Most TEAEs resolved by end‐of‐study. Significance: Fenfluramine treatment was associated with improved seizure outcomes and global functioning compared with placebo regardless of age, number of previous ASMs, and SCN1A status in patients with DS. Fenfluramine was well‐tolerated; no new safety signals were identified. Further studies with larger sample sizes (including adults) and a priori inferential analyses of stratified groups are warranted. Plain Language Summary: Patients with Dravet syndrome struggle with seizures and everyday life. In three studies, patients aged 2–18 years received fenfluramine or placebo (sugar pill). Fenfluramine lowered seizures without many side effects. Researchers combined results from these studies to see how fenfluramine worked in different patient groups based on age, number of previous medications, and a gene called SCN1A . They looked at seizure reduction and whether doctors felt patients had improved. In all groups, fenfluramine worked better than placebo, with similar side effects. Researchers believe fenfluramine helped these patients, but some groups were small, so these results need to be confirmed.

  • Open Access

    Prolonged fenfluramine use in open‐label studies of Dravet or Lennox–Gastaut syndromes: Long‐term safety, tolerability, patient global functioning, and considerations for interpreting effectiveness

    by Antonio Gil‐Nagel, Kelly G. Knupp, Boudewijn Gunning, Domenica Immacolata Battaglia, Elizabeth A. Thiele, Ingrid E. Scheffer, An‐Sofie Schoonjans, Rima Nabbout, Nathalie Villeneuve, Kerstin Alexandra Klotz, et al.

    Objective: Long‐term safety and global functioning are reported in patients with Dravet syndrome (DS) or Lennox–Gastaut syndrome (LGS) treated with fenfluramine in an open‐label extension (OLE) study after participating in a previous open‐label feeder study. Methods: Patients could enroll in this international, multicenter OLE (NCT03936777) after completing one of three fenfluramine open‐label studies. The latest feeder study fenfluramine dose was continued, then flexibly titrated (maximum: .7 mg/kg/day [26 mg/day] without stiripentol or .4 mg/kg/day [17 mg/day] with stiripentol), with ≥1 concomitant antiseizure medication administered. Primary endpoint was fenfluramine long‐term safety/tolerability. Global functioning using caregiver‐ and investigator‐reported Clinical Global Impression of Improvement (CGI–I) ratings, globally and for subdomains (cognition, behavior, motor function), at last visit relative to study baseline was evaluated. Overall treatment exposure and age groups were analyzed post hoc. Results: A total of 412 patients enrolled (DS: 265 [64.3%], LGS: 147 [35.7%]); 30.8% were ≥18 years old. Median fenfluramine treatment duration in this OLE was 729.5 days (range = 8–1544), and overall median fenfluramine exposure, including feeder studies, was 1464.5 days (range = 171–2800). In this OLE, ≥1 treatment‐emergent adverse event (TEAE) was reported in 311 (75.5%) patients; fenfluramine‐related (per investigator) serious TEAEs were reported in five (1.2%) patients. Three patients died in this OLE (deemed unrelated to fenfluramine by investigators). After starting this OLE already receiving fenfluramine, 373 of 401 (93.0%) and 376 of 401 (93.8%) patients were rated by caregiver and investigator, respectively, as “improved or no change” on CGI–I versus this study baseline; subdomain ratings of “improved or no change” were largely consistent with global assessment. Significance: In our OLE study of patients with DS or LGS treated with fenfluramine (up to 4 years), no new or unexpected safety signals were observed; global functioning was improved or stable (vs. study baseline) in >90% of patients, supporting long‐term fenfluramine use in pediatric and adult patients with DS or LGS.


  • Open Access

    Memantine treatment in individuals with GRIN gain‐of‐function variants is associated with improvements in behavior, development, and seizure frequency

    by Maike Karnstedt, Riley E. Perszyk, Scott J. Myers, Ellington McDaniels, Marta Somorai, Ingo Borggraefe, Danielle C. M. Veenma, An‐Sofie Schoonjans, Pasquale Striano, Tadeu A. Fantaneanu, et al.

    Objective: GRIN‐related disorders due to pathogenic variants in GRIN1 , GRIN2A , GRIN2B , or GRIN2D genes are associated with altered N‐methyl‐D‐aspartate receptor (NMDAR) function. Functional changes include gain (GoF) and loss of receptor function (LoF). Clinical reports describing the use of the NMDAR blocker memantine in GRIN‐related disorders show a diverse and inconsistent spectrum of treatment responses. Methods: To evaluate clinical responses to memantine, we collected retrospective data on 34 individuals with GRIN variants, including 20 unpublished and 14 published cases. Variants were reclassified following American College of Medical Genetics and Genomics guidelines, and six in vitro functional assays were used to assess receptor function. We compared individuals with pathogenic GoF versus LoF in terms of associated clinical improvements, memantine sensitivity, and variant localization within the gene. Results: In 19 of the 34 variants, a pathogenic likely or possible GoF of the receptor was detected. Fourteen of 19 individuals (74%) benefited from memantine, comprising improvements in behavior (71%), development (50%), and seizure frequency (39%). Individuals with either LoF or a functionally indeterminate or no effect GRIN variant (15/34 individuals) showed significantly less benefit from memantine treatment but nevertheless rare adverse events (3/15). An increased distance of the variant from the memantine binding site was associated with a clinical benefit. Significance: Our retrospective observational study outlines the importance of correct classification of GRIN variants with regard to pathogenicity and functional consequence prior to applying memantine or other precision medicine approaches in clinical trials. Furthermore, the distance from a GoF variant to the memantine binding site correlated with a positive treatment response and may, at least in part, explain different degrees of therapeutic benefit.


  • Open Access

    Final analysis from an open-label extension study of fenfluramine for the treatment of seizures in Lennox-Gastaut syndrome: long-term impact on patients and caregivers

    by Kelly G. Knupp, Ingrid E. Scheffer, An-Sofie Schoonjans, Joseph Sullivan, Lieven Lagae, Stéphane Auvin, Elizabeth A. Thiele, Renzo Guerrini, Sameer M. Zuberi, Rima Nabbout, et al.


  • Fibroblast transcriptomics uncovers pathogenic genomic variants in individuals with exome‐negative childhood onset epilepsy

    by Noor Smal, Charissa Millevert, Matthias De Wachter, Els De Vriendt, Zakaria Eddafir, An‐Sofie Schoonjans, Allan Bayat, Rikke Steensbjerre Møller, Davide Mei, Simona Balestrini, et al.

    Objective: This study aims to improve genetic diagnosis in childhood onset epilepsy with neurodevelopmental problems by utilizing RNA sequencing of fibroblasts to identify pathogenic variants that may be missed by exome sequencing and copy number variation analysis. Methods: We enrolled 41 individuals with childhood onset epilepsy and neurodevelopmental problems who previously had inconclusive genetic testing. Fibroblast samples were cultured and analyzed using RNA sequencing to detect aberrant expression, aberrant splicing, and monoallelic expression using the Detection of RNA Outlier Pipeline (DROP) pipeline. Detected events were correlated with phenotypes, and long‐read genome sequencing was performed on individuals with strong candidate events to identify the causal genomic variant. A systematic literature review on RNA sequencing in rare disorders was conducted to contextualize our findings. Results: RNA sequencing identified five strong candidate events in four individuals, affecting the genes QRICH1 , TSC1 , SMARCA1 , GNAI1 , and PTEN . (Likely) pathogenic genomic variants affecting expression of QRICH1 , TSC1 , and SMARCA1 were detected, resulting in a diagnostic yield of 7% (3/41). Two variants were not covered in the initial exome sequencing data but were revealed through long‐read sequencing. The identification of a pathogenic TSC1 variant led to a previously unrecognized diagnosis of tuberous sclerosis complex. This prompted guideline‐based screening, which revealed tuberous sclerosis lesions in the brain and lung, directly impacting clinical care. Notably, two of the three pathogenic events would not have been detected using whole blood due to the lack of expression of the involved genes. The lower yield of this study compared to studies in other rare disorders reflects the genetic heterogeneity of epilepsy and neurodevelopmental disorders, and the inaccessibility of affected tissue. Significance: This research underscores RNA sequencing of cultured fibroblasts as a valuable tool in genetic diagnostics for childhood onset epilepsy, particularly when conventional methods fail. Expanding the control dataset with age‐matched samples and incorporating RNA sequencing with nonsense‐mediated decay inhibition could further enhance diagnostic yield.


  • Seizure quantification in sunflower syndrome by a wrist‐worn device

    by Jo Sourbron, Renee Proost, Jan Vandenneucker, Valentina Ticcinelli, Filip Roelens, An‐Sofie Schoonjans, Els Sercu, Helene Verhelst, Katrien Jansen, Lieven Lagae

    Objective: Sunflower syndrome is a rare photosensitive childhood‐onset epilepsy, featuring repetitive handwaving events (HWE) triggered by light. Objective documentation of these HWE can be difficult due to the numerous events occurring daily and/or caregivers who document the seizures but are not always present. Hence, seizure diaries can be underreporting.Methods: We performed a feasibility study in three Belgian Sunflower syndrome individuals to assess the possibility to quantify the HWE by a wrist‐worn wearable device (Axivity AX6). We conducted a structured exercise aiming to capture patterns of possible confounders in a controlled environment. Subsequently, patients wore the device for three to six consecutive days and nights at home. Spectral power analyses were performed to characterize the frequency signature of the different movements.Results: The HWE of patient A and B showed homogeneity and narrow‐band frequencies. Patient C did not experience any HWE at the start of the study due to proper seizure control. Regarding HWE, there was a higher spectral power for Gyroscope Z (Gz) compared to Gy. The inter‐subject variability for HWE frequency peaks was in the 3–6 Hz range. Computer analysis by visual annotation, without checking the seizure diary, detected 71% of the HWE if the HWE lasted for longer than 5 s (sensitivity 64%). For shorter HWE duration, the detection rate was 50% but seemed to be higher if there was a concordant change of eye movement (63%) (sensitivity 36%). The most obvious confounder was toothbrushing (TB). However, TB showed a different pattern: that is, higher or comparable spectral power for Gy compared to Gz. There was also a higher or comparable spectral power for Gy compared to Gz for “waving hello”.Significance: We show that the wearable movement sensor Axivity AX6 can detect HWE in Sunflower syndrome individuals and distinguish them from confounders in a real‐world setting.


  • Peer support in paediatrics: A literature review

    by Sigrid Ansar, Amber Coveliers, Sarah De Bruyn, Toon Janssen, Roxanne Oostermeyer, Femke Wille, An‐Sofie Schoonjans, Stijn Verhulst

    Aim: Creating an overview of the existing literature about peer support in paediatrics, with a focus on children with chronic diseases.Methods: An online search was conducted in MEDLINE and Web of Science. English, Dutch or French articles published between 1 January 2000 and 10 May 2023 were included, based on title and Results: In this review, 47 articles were included, identifying following themes: Health‐Related Quality of Life (n = 8), peer support for parents/siblings (n = 6), social environment (n = 2), and peer support programme for children (n = 31) subdivided in: general concept (n = 13), online (n = 11), camps (n = 6), and development of a peer support programme (n = 1). Peer support aims to improve disease‐related knowledge, coping, and management of the disease, as well as creating a positive mindset and decreasing the disease burden. There is no consensus regarding which peer group design was superior.Conclusions: Peer groups aim to increase knowledge and psychological adaptation, and decrease physical symptoms and side effects. It is desired to start the peer mentor programme within 1 year after diagnosis or during a critical incident. Further investigation needs to determine the optimal age to start these groups and the format (online or in‐person). Communication between mentors and their mentees was crucial in the succeeding of the programme, as well as creating a safe environment to share experiences. Even though research is still needed concerning peer‐to‐peer support for children, there is already a lot known about similar programmes for parents of children with chronic diseases.


  • Open Access

    Comprehensive scoping review of fenfluramine's role in managing generalized tonic–clonic seizures in developmental and epileptic encephalopathies

    by Antonio Gil‐Nagel, J. Helen Cross, Orrin Devinsky, Berten Ceulemans, Lieven Lagae, Kelly Knupp, An‐Sofie Schoonjans, Philippe Ryvlin, Elizabeth A. Thiele, Shikha Polega, et al.

    Developmental and epileptic encephalopathies (DEEs) are characterized by pharmacoresistant seizures and developmental delay. Patients with DEEs experience multiple seizure types, including tonic–clonic seizures (TCS) that can be generalized tonic–clonic (GTCS) or focal evolving to bilateral tonic–clonic (FBTCS). Fenfluramine (FFA) has demonstrated efficacy in reduction of TCS in patients with Dravet syndrome (DS), Lennox–Gastaut syndrome (LGS), and other DEEs. Using the PRISMA‐ScR (Preferred Reporting Items for Systematic Review and Meta‐Analyses extension for Scoping Review) guidelines, we performed a scoping review to describe changes in TCS in patients treated with FFA. A comprehensive search of five literature databases was conducted up to February 14, 2023. Studies were included if they reported change in GTCS or TCS (but not FBTCS) after treatment with FFA in patients with DEEs. Duplicate patients and studies with unclear efficacy data were excluded. Fourteen of 422 studies met the eligibility criteria. Data extracted and evaluated by expert clinicians identified 421 unique patients with DS (in nine studies), CDKL5 deficiency disorder, SCN8A‐related disorder, LGS, SCN1B‐related disorder, and other DEEs. The median percent reduction in GTCS or TCS from baseline was available in 10 studies (n = 328) and ranged from 47.2% to 100%. Following FFA treatment, 10 studies (n = 144) reported ≥50% reduction in GTCS or TCS from baseline in 72% of patients; in nine of those (n = 112), 54% and 29% of patients achieved ≥75% and 100% reduction in GTCS or TCS from baseline, respectively. Overall, this analysis highlighted improvements in GTCS or TCS frequency when patients were treated with FFA regardless of the DEE evaluated. Future studies may confirm the impact of FFA on TCS reduction and on decreased premature mortality risk (including sudden unexpected death in epilepsy), improvement in comorbidities and everyday executive function, decreased health care costs, and improvement in quality of life.